在m6A阅读器IGF2BP2通过m6A-SLC1A5-mTORC1轴促进胰腺癌的进展
Xi Pu1, Yuting Wu1, Weiguo Long2
1Department of Gastroenterology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, 212001, China.
Cancer cell international
|March 29, 2025
概括
胰岛素样生长因子2 mRNA结合蛋白2 (IGF2BP2) 通过激活m6A-SLC1A5-mTORC1轴,影响谷氨酸代谢,促进胰腺癌. 向IGF2BP2为胰腺癌提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症新陈代谢 癌症新陈代谢
背景情况:
- 胰腺癌是一种高度攻击性的恶性瘤.
- 谷氨酸代谢对于瘤生长至关重要.
- N6-甲基氨酸 (m6A) 修饰调节癌症代谢,呈现出潜在的治疗标.
研究的目的:
- 调查m6A修饰在胰腺癌中的作用,特别是在谷氨酸代谢中的作用.
- 探索胰岛素样生长因子2的功能意义mRNA结合蛋白2 (IGF2BP2) 在胰腺癌的进展.
主要方法:
- 利用癌症基因组图谱 (TCGA) 和GEPIA进行数据分析.
- 采用体外和体内模型来研究IGF2BP2的影响.
- 应用了MeRIP-seq,MeRIP-PCR和RIP来识别SLC1A5作为IGF2BP2.2的直接目标.
主要成果:
- IGF2BP2和SLC1A5的高表达与胰腺癌预后不佳相关.
- 抑制IGF2BP2抑制了瘤生长和谷氨酸的摄取.
- IGF2BP2激活m6A-SLC1A5-mTORC1轴,促进胰腺癌的发生.
- 抑制IGF2BP2增加了对放射治疗和化疗的敏感性.
结论:
- IGF2BP2通过m6A-SLC1A5-mTORC1轴促进胰腺癌,影响谷氨酸代谢.
- 向IGF2BP2代表了胰腺癌的新疗法策略.
- 破坏m6A调节为增强当前胰腺癌治疗提供了新的见解.
相关概念视频
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
Abnormal Proliferation
4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
Metastasis
5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K


